Biotechnology Breast Cancer cancer Cancer Discovery Cancer screening Clinical Trials genes

New Study Finds Nanoparticles Show Promise in Therapy for Triple-Negative Breast Cancer

Approximately 10-20 percent of diagnosed breast cancers are found to be triple-negative, meaning the breast cancer cells test negative for estrogen and progesterone receptors as well as HER2 receptors, genes that can play a role in the development of breast cancer. Triple-negative breast cancer can be more aggressive and difficult to treat as the cancer cells do not respond to hormonal therapies or therapies that target HER2 receptors. A new
Biotechnology cancer Cell Therapy

Osteoporosis Drug Could Be Used to Treat Aggressive Form of Breast Cancer, Researchers Say

Researchers in China have discovered that an enzyme called UGT8 drives the progression of basal-like breast cancer, an aggressive form of the disease that is largely untreatable. But the study, which will be published May 4 in the Journal of Experimental Medicine, reveals that the widely used osteoporosis drug zoledronic acid inhibits UGT8 and prevents the spread of basal-like breast cancer in mice, suggesting that this drug could also be
Biotechnology cancer Cell Therapy Immunotherapies

Drug Combo Gangs Up to Take on Triple-Negative Breast Cancer

Researchers find novel combination disrupts multiple factors in aggressive type of cancer In the hunt for novel treatments against an aggressive form of breast cancer, researchers combined a new protein inhibitor with a chemotherapy drug to create a powerful combination that resulted in cancer cell death. Triple-negative breast cancer is a subtype that does not express hormone receptor or HER2. It occurs in approximately 15 percent of patients with breast
Biotechnology cancer Immunotherapies

UH Seidman Cancer Center Expert Presents Novel Triple-Negative Breast Cancer Immunotherapy Trial at 2016 San Antonio Breast Cancer Symposium

Meeting focuses on state-of-the-art breast cancer research, including immunotherapeutic approaches A researcher from University Hospitals Seidman Cancer Center discussed his upcoming immunotherapy clinical trial for triple-negative breast cancer at the 2016 San Antonio Breast Cancer Symposium. The annual symposium is the premier meeting for more than 7,500 physicians and scientists dedicated to breast cancer treatment, featuring state-of-the-art breast cancer research such as experimental biology, etiology, prevention, diagnosis, and therapy of
cancer

NUS Scientists Discover The “Switch” That Makes Breast Cancer Cells Aggressive

A team of scientists from the National University of Singapore (NUS) has established novel insights into the relationship between breast cancer tumour intracellular redox environment and the cancer cells’ ability to become invasive. The study by Dr Alan Prem Kumar from the Cancer Science Institute of Singapore (CSI Singapore) at NUS and NUS Yong Loo Lin School of Medicine, together with Professor Shazib Pervaiz and Associate Professor Marie-Veronique Clement from
cancer

Phosphorylated-p68 Drug With Efficacy in 100 Cancer Cell Lines to Target Triple Negative Breast Cancer

Drugs that target and destroy phosphorylated-p68 (P-p68), an RNA helicase, have the potential to kill cancer, without damaging other tissues as chemotherapy does. P-p68 has recently garnered attention as a molecular target in cancer therapy. It is an ideal target because P-p68 is overexpressed in cancer cells but absent in normal cells. P-p68 has shown to increase the activity of cancer related genes including cyclin D1, c-jun and c-myc. It
cancer

Inhibition of β2-Adrenergic Receptor Reduces Triple-Negative Breast Cancer Brain Metastases: The Potential Benefit of Perioperative β-Blockade.

While we look to invent new medicines to treat cancer, a parallel approach to repurpose existing medicines may be highly effective. Stress, mediated by adrenaline, has been suspected to promote cancer growth and this research study shows that by blocking adrenaline receptors in breast cancers, they are less successful in spreading to and growing in the brain. Background: Cancer cells are under the relentless drive to spread, this metastasis is